National Perspectives Plenary (1 CME)

(1.0 CME) In this conference recording from the 2018 Annual Conference, connect with the innovators shaping the field at the national level. ASAM President Kelly J. Clark, MD, MBA, DFASAM, moderates an informal conversation with representatives from NIAAA, NIDA, and the CDC. The conversation includes questions on emerging issues and advances in addiction medicine, increasing the addiction medicine workforce, and improving the quality of care for patients.

George F. Koob

PhD

George F. Koob, PhD is Director of the National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health, Washington, DC. As an authority on alcoholism, drug addiction and stress, he has contributed to our understanding of the neurocircuitry associated with the acute reinforcing effects of alcohol and drugs of abuse and the neuroadaptations of the reward and stress circuits associated with the transition to dependence. Dr. Koob has published over 650 peer reviewed papers and several books including the “Neurobiology of Addiction," a comprehensive treatise on emerging research in the field. He has mentored 11 PhD students and over 75 post-doctoral fellows.

Wilson Compton

MD, MPE

Dr. Wilson M. Compton serves as the Deputy Director of the National Institute on Drug Abuse (NIDA) of the National Institutes of Health. In his current role, Dr. Compton's responsibilities include providing scientific leadership in the development, implementation, and management of NIDA's research portfolio and working with the Director to support and conduct research to improve the prevention and treatment of drug abuse and addiction. Prior to his current appointment, Dr. Compton served as the Director of NIDA's Division of Epidemiology, Services and Prevention Research from 2002 until 2013. In this leadership role, he oversaw the scientific direction of a complex public health research program of national and international scope addressing: 1) the extent and spread of drug abuse, 2) how to prevention drug abuse, and 3) how to implement drug abuse prevention and treatment services as effectively as possible. Before joining NIDA, Dr. Compton was Associate Professor of Psychiatry and Director of the Master in Psychiatric Epidemiology Program at Washington University in Saint Louis as well as Medical Director of Addiction Services at the Barnes-Jewish Hospital in Saint Louis. Dr. Compton received his undergraduate education from Amherst College. He attended medical school and completed his residency training in psychiatry at Washington University. During his career, Dr. Compton has achieved multiple scientific accomplishments: he was selected to serve as a member of the DSM-5 Revision Task Force; is the author of more than 130 articles and chapters; and is an invited speaker at multiple high-impact venues. Dr. Compton is the recipient of multiple awards and in 2008, he received the Senior Scholar Health Services Research Award from the American Psychiatric Association, in 2010 the Paul Hoch Award from the American Psychopathological Association, in both 2012 and 2013, he was selected to receive the Leveraging Collaboration Award from the Food and Drug Administration. In 2013, Dr. Compton received the prestigious Health and Human Services Secretary's Award for Meritorious Service.

Debbie Dowell

MD, MPH

Debbie Dowell is Senior Medical Advisor/Chief Medical Officer for the Division of Unintentional Injury Prevention at the Centers for Disease Control and Prevention (CDC), CDR in the US Public Health Service, and was the lead author of the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain. She previously led CDC’s Prescription Drug Overdose Team and served as advisor to New York City’s Health Commissioner. Dr. Dowell completed residency and chief residency in Primary Care Internal Medicine at the NYU School of Medicine, where she later joined the faculty as a clinical assistant professor. Dr. Dowell is Board Certified in Internal Medicine and practiced medicine at a community health center in New York City.

She has conducted research on quality and safety in medical care, on the effects of clinical guidelines, and on the effectiveness of interventions to prevent opioid overdose, including Prescription Drug Monitoring Programs and academic detailing. She received her BA and MD from Columbia University, her MPH from the Johns Hopkins Bloomberg School of Public Health, and is a graduate of CDC’s Epidemic Intelligence Service (EIS).

Kelly Clark (Moderator)

MD, MBA, DFASAM, DFAPA

Dr. Kelly J. Clark is the President Elect of ASAM. She currently chairs the Public Policy Council, consisting of the Legislative Advocacy, Payer Relations, and Public Policy Committees.

Board certified in addiction medicine and psychiatry, she has focused her career on issues of prescription drug abuse, evidence informed behavioral health care, and payment reform. Dr. Clark is Chief Medical Officer of CleanSlate Centers, a multi-state medical group currently treating over 5,000 opioid addicted patients with medication management, and which has received a SAMHSA Science to Service Award for Office Based Opioid Treatment. She is active on the Association of Managed Care Pharmacy's Addiction Treatment Advisory Group; served on the writing committee of the Johns Hopkins Bloomberg School of Public Health's recent policy document, “The Prescription Drug Epidemic: An Evidence Based Approach”; and led the workgroup on Health Systems and Reimbursement at SAMHSA's Buprenorphine Summit.

As the Behavioral Health Medical Director of CDPHP, a non-profit health plan in New York, she provided the clinical leadership for in-sourcing the management of behavioral health benefits. As Chief Medical Officer for Behavioral Health Group, she again focused on opioid addiction. Her expertise in payment models, quality metrics, medical-behavioral health integration, and clinical care delivery systems, as well as her clinical work treating people with addictive disease, all allow her to offer insights and recommendations to address the current epidemic.

As faculty of the University of Massachusetts Medical School for eight years, Dr. Clark trained students and resident physicians on addiction. She is currently a member of the American Psychiatric Association's Integrated Care Work Group; the National Rx Drug Abuse Summit Advisory Board; and the faculty of the Virginia Tech Carilion School of Medicine.

ACCME Accredited with Commendation

ACCME Accreditation Statement

The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement

The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABPM Maintenance of Certification (MOC)

The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credits towards ABPM MOC Part II requirements.

ABAM Transitional Maintenance of Certification (tMOC)

This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of AMA PRA Category 1 Credit(s)™ for completing this course.

Key:

Complete
Failed
Available
Locked
Session Recording
Open to view video.
Open to view video. Watch the conference recording.
CME Quiz
3 Questions
3 Questions 3 Questions
CME Evaluation
15 Questions
CME Credit and Certificate
Up to 1.00 medical credits available  |  Certificate available
Up to 1.00 medical credits available  |  Certificate available 1 AMA PRA Category 1 Credit(s)™